Wildy logo
(020) 7242 5778

Wildy’s Book News

Book News cover photo

Vol 21 No 9 Sept/Oct 2016

Book of the Month

Cover of Goode on Commercial Law

Goode on Commercial Law

Edited by: Ewan McKendrick
Price: £170.00

Pupillage & Student Offers

Special Discounts for Pupils, Newly Called & Students

Read More ...

Secondhand & Out of Print

Browse Secondhand Online


Acceptable Risk in Biomedical Research: European Perspectives

ISBN13: 9789400726772
Published: January 2012
Publisher: Springer-Verlag
Country of Publication: Germany
Format: Hardback
Price: £117.00

Despatched in 10 to 12 days.

This book is the first major work that addresses a core question in biomedical research: the question of acceptable risk. The acceptable level of risks is regulated by the requirement of proportionality in biomedical research law, which state that the risk and burden to the participant must be in proportion to potential benefits to the participant, society or science. This investigation addresses research on healthy volunteers, children, vulnerable subjects, and includes placebo controlled clinical trials. It represents a major contribution towards clarifying the most central, but also the most controversial and complex issue in biomedical research law and bioethics. The EU Clinical Trial Directive, the Council of Europe's Oviedo Convention (and its Additional Protocol), and national regulation in member states are covered. It is a relevant work for lawyers and ethicists, and the practical approach makes a valuable tool for researchers and members of research ethics committees supervising biomedical research.

Medical Law
1. Introduction 2. Method and material 3. Initial conceptual clarifications 4. Origins of the requirement of proportionality 5. The purpose of the requirement of proportionality 6. Introduction: Part II 7. Which risks, burdens and potential benefits are relevant? 8. How to estimate risks, burdens, and potential benefits 9. The requirement of proportionality -- initial clarifications 10. Therapeutic research 11. Nontherapeutic research 12. Nontherapeutic research on "vulnerable" participants 13. Non-interference with necessary clinical interventions and the no harm rule 14. Especially on randomised clinical trials, including placebo controlled clinical trials 15. Acceptable Risks and Burdens to Others than the Participant 16. Later developments during the course of the research 17. Legal effects of the requirement of proportionality 18. Summary of results 19. Recommendations 20. Perspectives 21. Appendix